

FAX

GlaxoSmithKline

To Examiner B. Robinson, Group 1625
.....
Company USPTO
.....
Fax 703-872-9306
.....
From Valerie L. Phillips
.....
Tel 919-483-8223
.....
E-mail Vlp47157@gsk.com
.....
Date 22-Feb-2002 Pages including cover 21
.....
Subject PG3602USW
.....

GlaxoSmithKline
PO Box 13398
Five Mays Drive
Research Triangle Park
North Carolina 27709
Tel: 919 483 2100
www.gsk.com

FAX RECEIVED**FEB 25 2002****GROUP 1600****OFFICIAL**

RE: Response to official action dated 12/04/2001.
Applicant: I Campbell et al.
Serial No. 09/830,836
Filed 1 May 2001
Group Art 1625
Examiner B. Robinson
Title: PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2-INHIBITORS

Items being sent:

1. Transmittal and response to official action dated 12/04/2001
2. Copies of postcard, IDS and PTO-1449 submitted 9/28/01

NOTE: Copies of references cited in IDS dated 9/28/01 being mailed via US Mail under separate cover.

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)

Applicant(s): I Campbell et al.

Docket No.

PG3602USW

Serial No.

09/830,836

Filing Date

1 May 2001

Examiner

B. Robinson

Group Art Unit

1625

Invention: PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2-INHIBITORS

FAX RECEIVED

FEB 25 2002

GROUP 1600**OFFICIAL**I hereby certify that this response to official action dated 12/04/2001 and accompanying paperwork
(Identify type of correspondence)is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. 703-872-9306)

on

02/22/02

(Date)

Valerie L. Phillips

(Typed or Printed Name of Person Signing Certificate)

Valerie L. Phillips

(Signature)

Note: Each paper must have its own certificate of mailing.

P18REV01

AMENDMENT TRANSMITTAL LETTER (Large Entity)Applicant(s): **L. Campbell et al.**

Docket No.

PG3602USW

Serial No.

09/830,836

Filing Date

1 May 2001

Examiner

B. Robinson

Group Art Unit

1625Invention: **PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2-INHIBITORS****TO THE ASSISTANT COMMISSIONER FOR PATENTS:**


Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

CLAIMS AS AMENDED

| | CLAIMS REMAINING AFTER AMENDMENT | HIGHEST # PREV. PAID FOR | NUMBER EXTRA CLAIMS PRESENT | RATE | ADDITIONAL FEE |
|--|-------------------------------------|-----------------------------|--------------------------------|---------|-------------------|
| TOTAL CLAIMS | 31 - | 31 = | 0 x | \$18.00 | \$0.00 |
| INDEP. CLAIMS | 5 - | 5 = | 0 x | \$84.00 | \$0.00 |
| Multiple Dependent Claims (check if applicable) <input type="checkbox"/> | | | | | \$0.00 |
| TOTAL ADDITIONAL FEE FOR THIS AMENDMENT | | | | | \$0.00 |

- ☒ No additional fee is required for amendment.
- ☐ Please charge Deposit Account No. _____ in the amount of _____
A duplicate copy of this sheet is enclosed.
- ☐ A check in the amount of _____ to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. **07-1392**
A duplicate copy of this sheet is enclosed.
- ☒ Any additional filing fees required under 37 C.F.R. 1.16.
- ☒ Any patent application processing fees under 37 CFR 1.17.


SignatureDated: **22 Feb 02**

Lorie Ann Morgan
Registration No. 38,181
Telephone 919-483-8222
Facsimile 919-483-7988

**23347**

PATENT TRADEMARK OFFICE

CC:

I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Correspondence

P111LARGE/REV08

COPY

DOCKET NO.: PG3602 USW
SERIAL NO.: 097830 836
TITLE: PIRAZOTOPYRIDINE Derivatives AS Selective Cox-2...
The date stamp of the Patent Office hereon may be considered as the date on which
papers indicated below are received.

☐ Application _____ pages _____ claims
☐ Abstract
☐ Assignment w/Coverletter
☐ Drawings (_____ sheets)
☒ Declaration/Oath w/Power of Attorney ☐ Unexecuted ☐ Executed
☒ Fee Authorization & Deposit Account Copy
☒ IDS-Publication Disclosure (37 CFR 1.56) ☐ w/o References ☒ w/References
☐ Amendment (_____)
☐ Petition for Extension of Time ☐ 1mo ☐ 2mo ☐ 3mo ☐ 4mo
☐ Issue Fee Transmittal
☐ Notice of Appeal
☐ Appeal Brief
☐ Req. for Oral Hearing
☒ Certificate of Mailing ☒ Express Mail ☒ 1st Class
Resp to Restriction Request

9/28/01
CUE

PG3602USW

#10/B
mg
3/6/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application:

I. Campbell et al.,

Serial No.: 09/830,836

Examiner: B. Robinson

Filing Date: 1 May 2001

Art Unit: 1625

For: PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS

Commissioner of Patents
Washington D.C. 20231RESPONSE


Sir:

Responsive to the Office Action mailed 4 December 2001, please amend and reconsider the instant application in view of the following amendments and remarks.

AmendmentIn the Claims:

Please amend claims 1-5 as follows. The following clean claims reflect the amendments being made herein. The following is a complete set of claims as pending after the instant amendment. For convenience, a marked-up copy of the amended claims is attached hereto.

1. (Twice Amended) A compound of formula (I)



and pharmaceutically acceptable derivatives thereof wherein